On 27 March, Ausnutria Dairy Corporation Ltd (Stock Code: 1717.HK, hereinafter referred to as Ausnutria or the Company) officially released…
Browsing: HealthCare
RESULTS HIGHLIGHTS: – The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of…
– Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million,…
– Innovation and R&D Advance Steadily, RMB 31.83 Billion in Revenue Recorded – Underlying Profit Attributable to Owners of the…
Formerra, a leader in performance materials distribution, announced the implementation of a transportation surcharge to address continued cost escalation across…
On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its…
Wellgistics Health, Inc. (Wellgistics or the Company) (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of…
– Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position Key Results Highlights: – Revenue Growth: 8.6% increase to approximately HK$1,813.8…
Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited (CORXEL).…
Pacific Avenue Capital Partners (Pacific Avenue), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions…
March 9, Everest Medicines (HKG: 1952) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by…
International Women’s Day: Why Menopause May Be a Missed Cardiovascular Risk Window As International Women’s Day prompts renewed focus on…
Formerra, LLC (Formerra), a leading distributor of engineered thermoplastic resins, additives, elastomers, and other specialty materials, today announced the appointment…
– First glucokinase-activator (GKA) approval outside mainland China – Approval supports a differentiated approach to Type 2 diabetes (T2D) management…
– Exhibition space fully secured prior to the show, reflecting strong exhibitor confidence in Northern Vietnam’s laboratory and scientific markets…
CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by…
Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration…
12 February 2026, Modern Dental Group Limited (Modern Dental or the Group, HKG: 3600), a leading global dental prosthetic device provider,…
Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial…
Essex Bio-Technology Limited (EssexBio or the Company; HKG: 1061) today announces its successful participation in the 41st Asia-Pacific Academy of…